AU2019416330A1 - Galectin-3 inhibiting c-glycosides - Google Patents

Galectin-3 inhibiting c-glycosides Download PDF

Info

Publication number
AU2019416330A1
AU2019416330A1 AU2019416330A AU2019416330A AU2019416330A1 AU 2019416330 A1 AU2019416330 A1 AU 2019416330A1 AU 2019416330 A AU2019416330 A AU 2019416330A AU 2019416330 A AU2019416330 A AU 2019416330A AU 2019416330 A1 AU2019416330 A1 AU 2019416330A1
Authority
AU
Australia
Prior art keywords
compound
groups
chosen
subject
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019416330A
Other languages
English (en)
Inventor
Indranath Ghosh
John L. Magnani
Jason NOGUIERA
John M. Peterson
Arun K. Sarkar
Yusufbhai U. VOHRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crescent Biopharma Inc
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Publication of AU2019416330A1 publication Critical patent/AU2019416330A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2019416330A 2018-12-27 2019-12-26 Galectin-3 inhibiting c-glycosides Abandoned AU2019416330A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862785588P 2018-12-27 2018-12-27
US62/785,588 2018-12-27
US201962927192P 2019-10-29 2019-10-29
US62/927,192 2019-10-29
PCT/US2019/068597 WO2020139960A1 (en) 2018-12-27 2019-12-26 Galectin-3 inhibiting c-glycosides

Publications (1)

Publication Number Publication Date
AU2019416330A1 true AU2019416330A1 (en) 2021-07-01

Family

ID=69191291

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019416330A Abandoned AU2019416330A1 (en) 2018-12-27 2019-12-26 Galectin-3 inhibiting c-glycosides

Country Status (9)

Country Link
US (1) US11873317B2 (cg-RX-API-DMAC7.html)
EP (1) EP3902797A1 (cg-RX-API-DMAC7.html)
JP (1) JP7547345B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210110645A (cg-RX-API-DMAC7.html)
CN (2) CN113490665B (cg-RX-API-DMAC7.html)
AU (1) AU2019416330A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021012482A2 (cg-RX-API-DMAC7.html)
CA (1) CA3122321A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020139960A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7547345B2 (ja) 2018-12-27 2024-09-09 グリコミメティクス, インコーポレイテッド ガレクチン-3阻害性c-グリコシド
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN115244045A (zh) * 2019-12-24 2022-10-25 糖模拟物有限公司 抑制半乳凝素-3的c-糖苷酮、醚和醇
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2022073969A1 (en) * 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
US12291520B2 (en) * 2020-11-02 2025-05-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives
WO2022241183A1 (en) 2021-05-14 2022-11-17 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
WO2022250976A1 (en) * 2021-05-28 2022-12-01 Glycomimetics, Inc. Galectin-3 inhibiting c-glycoside oximes
WO2024220435A1 (en) * 2023-04-18 2024-10-24 Truebinding, Inc. Methods of treating eye disease

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK455088D0 (da) 1988-08-12 1988-08-12 Symbicom Ab Syntetiske receptoranaloger
CA2106301C (en) 1991-03-18 1999-04-06 Chi-Huey Wong Oligosaccharide enzyme substrates and inhibitors: method and compositions
US5620864A (en) 1992-06-29 1997-04-15 Health Research, Inc. Acceptor for fucosyl transferase
DK76193D0 (da) 1993-06-25 1993-06-25 Astra Ab Kulhydratderivater
DE19643764A1 (de) 1996-09-30 1998-04-02 Bayer Ag Glycokonjugate von modifizierten Camptothecin-Derivaten (20-0-Verknüpfung)
DE19654180A1 (de) 1996-12-23 1998-06-25 Hoechst Ag Phosphane, Verfahren zu ihrer Herstellung und ihre Verwendung in Metallkomplexen
US6323176B1 (en) 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
WO2000035945A1 (en) 1998-12-16 2000-06-22 Eli Lilly And Company Cyclic peptide antifungal agents having a sugar substituent
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
FR2835527B1 (fr) 2002-02-05 2004-03-12 Centre Nat Rech Scient Synthese de molecules de type inositolphosphate glycanne: traitement des troubles de la proliferation cellulaire et des desordres metaboliques caracterises par une resistance a l'insuline
AUPS213802A0 (en) 2002-05-03 2002-06-06 Alchemia Pty Ltd Disaccharides for drug discovery
CA2528152A1 (en) 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
WO2005061523A1 (en) 2003-12-23 2005-07-07 Progen Industries Limited Glycosaminoglycan (gag) mimetics
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
EP1632498A1 (en) 2004-09-03 2006-03-08 Syngenta Participations AG Derivatives of avermectin, avermectin monosaccharide and avermectin aglycone
WO2007021721A2 (en) 2005-08-09 2007-02-22 Glycomimetics, Inc. Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas
US20090214439A1 (en) 2006-03-15 2009-08-27 Trustees Of Tufts College Fluorinated Carbohydrates and Their Use in Tumor Visualization, Tissue Engineering, and Cancer Chemotherapy
US20090176717A1 (en) 2006-06-01 2009-07-09 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
EP1964846A1 (en) 2007-02-27 2008-09-03 Bracco Imaging, S.P.A. Process for the preparation of contrast agents
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
KR102085687B1 (ko) 2008-04-08 2020-03-06 슬로안-케테링인스티튜트퍼캔서리서치 트리테르펜 사포닌, 그의 합성 방법, 및 그의 용도
US8697862B2 (en) 2008-05-16 2014-04-15 Galecto Biotech Ab Synthesis of galactoside inhibitors
US9220767B2 (en) 2008-10-08 2015-12-29 Abivax Vaccine composition for use against influenza
ES2652488T3 (es) 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
WO2011002673A1 (en) 2009-07-01 2011-01-06 Temple University - Of The Commonwealth System Of Higher Education Leptin agonist and methods of use
US9624255B2 (en) 2009-08-11 2017-04-18 Arizona Board Of Regents Carbohydrate-mediated tumor targeting
WO2011129314A1 (ja) 2010-04-13 2011-10-20 和光純薬工業株式会社 糖類の重水素化方法
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
WO2013170985A1 (en) 2012-05-18 2013-11-21 Boettger Erik C New aminoglycoside antibiotics targeting bacterial 16s ribosomal rna lacking ototoxicity
EP2859112A4 (en) 2012-06-08 2015-10-28 Glycom As PROCESS FOR THE PREPARATION OF OLIGOSACCHARIDES AND OLIGOSACCHARIDE GLYCOSIDES BY FERMENTATION
GB201214736D0 (en) 2012-08-17 2012-10-03 Isis Innovation Inflammation imaging and therapy
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
IN2015DN02573A (cg-RX-API-DMAC7.html) 2012-10-31 2015-09-11 Galecto Biotech Ab
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
GB2511137A (en) 2013-02-26 2014-08-27 Glykos Finland Oy Chelator Molecule
AU2014236356A1 (en) 2013-03-14 2015-09-24 The Regents Of The University Of California Thiosaccharide mucolytic agents
DK2991683T3 (da) 2013-05-02 2019-11-04 Glykos Finland Oy Konjugater af et glykoprotein eller en glykan med en toksisk ladning
US20170095496A1 (en) 2014-04-08 2017-04-06 Galecto Biotech Ab Galactoside inhibitors for new uses
FR3020952B1 (fr) 2014-05-14 2017-09-08 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
WO2015197082A1 (en) 2014-06-27 2015-12-30 Glycom A/S Oligosaccharide production
JP6735680B2 (ja) 2014-07-09 2020-08-05 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤
US20170274087A1 (en) 2014-09-19 2017-09-28 Emory University Saccharide analogs and agents for the diagnosis and therapy of bacterial infections
WO2016113335A1 (en) 2015-01-16 2016-07-21 Galecto Biotech Ab Novel galactoside inhibitor of galectins
CA2970062C (en) * 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
US11406655B2 (en) 2015-05-12 2022-08-09 Galecto Biotech Ab Once-daily treatment of pulmonary fibrosis
US10799522B2 (en) 2015-07-27 2020-10-13 Wayne State University Compositions and methods relating to galectin detection
CA3000924A1 (en) 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
CN109563119A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
KR102626669B1 (ko) 2017-05-12 2024-01-17 갈랙틴 사이언시즈, 엘엘씨 질환의 예방 및 치료를 위한 화합물 및 이의 용도
CA3062649A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
US11267811B2 (en) 2017-09-27 2022-03-08 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2019075045A1 (en) 2017-10-11 2019-04-18 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
US11548908B2 (en) 2017-12-29 2023-01-10 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
JP7547345B2 (ja) 2018-12-27 2024-09-09 グリコミメティクス, インコーポレイテッド ガレクチン-3阻害性c-グリコシド
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CA3136661A1 (en) 2019-04-24 2020-10-29 Glycomimetics, Inc. Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors
WO2021086816A1 (en) 2019-10-29 2021-05-06 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides

Also Published As

Publication number Publication date
CN113490665A (zh) 2021-10-08
EP3902797A1 (en) 2021-11-03
US11873317B2 (en) 2024-01-16
WO2020139960A1 (en) 2020-07-02
CA3122321A1 (en) 2020-07-02
JP7547345B2 (ja) 2024-09-09
KR20210110645A (ko) 2021-09-08
CN118373810A (zh) 2024-07-23
BR112021012482A2 (pt) 2021-09-08
JP2022516075A (ja) 2022-02-24
CN113490665B (zh) 2024-05-07
US20220073555A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
US11873317B2 (en) Galectin-3 inhibiting c-glycosides
AU2018395417B2 (en) Heterobifunctional inhibitors of E-selectin and galectin-3
US20240165139A1 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
US20240150388A1 (en) Heterobifunctional inhibitors of e-selectin and galectin-3
AU2020263266A1 (en) Galactose-linked multimeric glycomimetic inhibitors of E-selectins, galectin-3, and/or CXCR4 chemokine receptors
WO2021086816A1 (en) Galectin-3 inhibiting c-glycosides
KR20230104190A (ko) 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
US20240287121A1 (en) Galectin-3 inhibiting c-glycoside oximes
US20240270724A1 (en) Galectin-3 inhibiting c-glycosides
US20230091472A1 (en) Galectin-3 inhibiting c-glycoside ketones, ethers, and alcohols

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application